Determining the Safety and Effectiveness of ENDOR Oral Combination Drug in the Treatment of Patients With COVID-19: A Randomized Controlled Trial

Abstract

The novel coronavirus caused by SARS-CoV-2 is still a public health concern as it can have dire consequences. Anti-inflammatory drugs are promising. Therefore, this study aimed to determine the safety and effectiveness of the ENDOR oral combination drug in the treatment of patients with COVID-19. This double-blinded, randomized controlled trial was conducted at the Imam Khomeini Hospital complex in Tehran, Iran. All COVID-19 patients who were admitted to the Imam Khomeini hospital complex from April 2022 to April 2023 and who were 18-75-Year-Old signed the consent form to participate in this study, were not pregnant, and did not need mechanical ventilation at admission. In this study of 200 patients (50% in the Endor group and 50% in the placebo group), 56.8% were male, and the mean age was 65.02±14.94. There were no statistically significant differences observed between the Endor and control groups across time for temperature (P=.075), WBC (P=.095), CRP (P=.108), sodium (P=.323), or calcium (P=.352). The slope of the decrease in ESR and the body temperature, as well as the slope of the increase in oxygen saturation in the Endor group, was higher than in the control group. Statistically significant differences between the Endor and control groups over time for respiratory rate (P=.003), oxygen saturation (P<.001), and potassium (P=.031) were observed. The decreasing slope of the respiratory rate in the Endor group was significantly higher than in the control group. ENDOR with anti-inflammatory features helps COVID-19 hospitalized patients recover faster by improving oxygen saturation, lowering fever, and decreasing respiratory rate.